We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Monday
May 18
10:30 - 11:30
K2
Urological cancers 4
Ann Henry, United Kingdom
Poster Discussions
Clinical
10:30 - 11:30
Changes in health-related quality of life in patients with prostate cancer initiating triptorelin: focus on age groups
Igor Latorzeff, France
-1917
10:30 - 11:30
Comparison of mpMRI and Biopsies for Identifying Radiorecurrent Prostate Cancer: GETUG-31 Ancillary Study
David Pasquier, France
-3082
10:30 - 11:30
Tumor-targeted dose escalation for localized prostate cancer using MRguided HDR brachytherapy or integrated VMAT boost: Long-term outcomes
Noelia Sanmamed Salgado, Spain
-1234
10:30 - 11:30
Treatment-Related Adverse Events Using Stereotactic Body Radiotherapy for Localised Prostate Cancer: A National Population-Based Study
Joanna Dodkins, United Kingdom
-1085
10:30 - 11:30
Cyberknife UH-SBRT for localized Prostate cancer and DIL: preliminary report of acute and late side effects of the prospective PRO-SPEED trial
Karl Amin, Italy
-3093
10:30 - 11:30
EARLY FINDINGS FROM THE STARR (NCT05455736) TRIAL:STEREOTACTIC SALVAGE RADIOTHERAPY FOR MACROSCOPIC RECURRENCE IN THE PROSTATE BED POST-PROSTATECTOMY
Niccolò Bertini, Italy
-3031
10:30 - 11:30
Current practices in PSMA-PET guided radiotherapy for prostate cancer: Results from the Co-IMPACT consortium international survey
Tobias Hölscher, Germany
-2311
10:30 - 11:30
Non-Invasive Urodynamic Analysis of Prostatic Urethral Lift with Stereotactic Radiotherapy for Prostate Cancer and Benign Prostate Hyperplasia
Aurelie Garant, USA
-548
10:30 - 11:30
Pooled analysis of observational studies in prostate cancer: quality of life changes in 1723 patients, 6 months after initiation of triptorelin
Igor Latorzeff, France
-855
10:30 - 11:30
Dominant Intraprostatic Lesion Simultaneous Integrated Boost (SIB-DIL) in Prostate Single-Dose Radiotherapy (SDRT) for unfavorable intermediate risk
Carlo Greco, Portugal
-4557